Evidence map›Paper›PMID 32992328›Full record

ArticleThe Journal of infectious diseases2021

Epitope-Specific Antibody Responses to a Plasmodium falciparum Subunit Vaccine Target in a Malaria-Endemic Population.

DeAnna J Friedman-Klabanoff, Mark A Travassos, Olukemi O Ifeonu, Sonia Agrawal, Amed Ouattara, Andrew Pike, Jason A Bailey, Matthew Adams, Drissa Coulibaly, Kirsten E Lyke and 11 more

Open access · greenAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 2 countries.

DeAnna J Friedman-KlabanoffCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-0373-4643
Mark A TravassosCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-6045-3322
Olukemi O IfeonuInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Sonia AgrawalCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Amed OuattaraCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Andrew PikeCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Jason A BaileyCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Matthew AdamsCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Drissa CoulibalyMalaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali.
Kirsten E LykeCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Matthew B LaurensCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Shannon Takala-HarrisonCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Bourema KouribaMalaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali.
Abdoulaye K KoneMalaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali.
Ogobara K DoumboMalaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali.
Jigar J PatelRoche Sequencing Solutions, Madison, Wisconsin, USA.
Mahamadou A TheraMalaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali.
Philip L FelgnerDivision of Infectious Diseases, Department of Medicine, University of California, Irvine, California, USA.
John C TanRoche Sequencing Solutions, Madison, Wisconsin, USA.
Christopher V PloweCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Andrea A BerryCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-3140-3868
University of Maryland, Baltimore · USUniversité des Sciences, des Techniques et des Technologies de Bamako · MLUniversity of California, Irvine · US

Funding

Technology CoreU19AI110820 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI RASKO, DAVID A · 2014 to 2023
$36.5M
FELLOWSHIP TRAINING PROGRAM IN VACCINOLOGYT32AI007524 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Marcelo B. Sztein · 1997 to 2026
$6.4M
Safety, Immunogenicity and Efficacy of VaccineU19AI065683 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BLACKWELDER, WILLIAM C. · 2005 to 2009
$4.7M
MALARIA RESEARCH TRAINING IN MALID43TW001589 · FIC · UNIVERSITY OF MARYLAND BALTIMORE · PI PLOWE, CHRISTOPHER V. · 2000 to 2015
$2.8M
Malaria:Clinical Research and Trial Preparation Sites-26685346N01AI085346 · NIAID · Univ Maryland · 1998 to 2004
$2.8M
Variant surface antigens in cerebral malaria pathogenesisR01HL130750 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI FISHER, STEVEN A., PLOWE, CHRISTOPHER V. · 2015 to 2018
$2.1M
Protein microarray antibody responses to P. falciparum in a human challenge modelK23AI125720 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BERRY, ANDREA · 2017 to 2021
$915k
Designing a diversity-covering multiantigen multi-strain vaccineK01HL140285 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI OUATTARA, AMED · 2019 to 2023
$712k
Ultra-dense peptide array analysis of naturally acquired and vaccine-induced P. falciparum immunityR21AI119733 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BERRY, ANDREA · 2016 to 2017
$361k
FIC NIH HHS D43 TW001589NHLBI NIH HHS K01 HL140285NHLBI NIH HHS R01 HL130750NIAID NIH HHS K23 AI125720NIAID NIH HHS N01AI85346NIAID NIH HHS R21 AI119733NIAID NIH HHS T32 AI007524NIAID NIH HHS U19 AI065683NIAID NIH HHS U19 AI110820
6 · The paper itself

Abstract

Circumsporozoite protein (CSP) coats the Plasmodium falciparum sporozoite surface and is a major malaria subunit vaccine target. We measured epitope-specific reactivity to field-derived CSP haplotypes in serum samples from Malian adults and children on a custom peptide microarray. Compared to children, adults showed greater antibody responses and responses to more variants in regions proximal to and within the central repeat region. Children acquired short-lived immunity to an epitope proximal to the central repeat region but not to the central repeat region itself. This approach has the potential to differentiate immunodominant from protective epitope-specific responses when combined with longitudinal infection data.

Indexed as

Antibody FormationMalaria, FalciparumMalaria VaccinesAdultAntibodies, ProtozoanChildEpitopesHumansMaliPlasmodium falciparumProtozoan ProteinsVaccines, SubunitAntibodies, ProtozoanEpitopesMalaria VaccinesProtozoan ProteinsVaccines, Subunitcircumsporozoite proteinmalariapeptide microarrayPlasmodium falciparum

Identifiers

PMID32992328
PMCPMC8176638
OpenAlexW3090182998

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.